参考文献/References:
[1] Yang C,Gao B,Zhao X,et al. Executive summary for China Kidney Disease Network(CK-NET) 2016 Annual Data Report[J]. Kidney Int,2020,98(6):1419-1423.
[2] Huo Y,van de Werf F,Han Y,et al. Long-term antithrombotic therapy and clinical outcomes in patients with acute coronary syndrome and renal impairment:insights from EPICOR and EPICOR Asia[J]. Am J Cardiovasc Drugs,2021,21(4):471-482.
[3] Natale P,Palmer SC,Saglimbene VM,et al. Antiplatelet agents for chronic kidney disease[J]. Cochrane Database Syst Rev,2022,2(2):CD008834.
[4] Stefanini GG,Briguori C,Cao D,et al. Ticagrelor monotherapy in patients with chronic kidney disease undergoing percutaneous coronary intervention:TWILIGHT-CKD[J]. Eur Heart J,2021,42(45):4683-4693.
[5] Lee SH,Lee SY,Chun WJ,et al. Clopidogrel monotherapy in patients with and without on-treatment high platelet reactivity:a SMART-CHOICE substudy[J]. EuroIntervention,2021,17(11):e888-e897.
[6] Pereira NL,Rihal CS,So DYF,et al. Clopidogrel pharmacogenetics[J]. Circ Cardiovasc Interv,2019,12(4):e007811.
[7] Jeong KH,Cho JH,Woo JS,et al. Platelet reactivity after receiving clopidogrel compared with ticagrelor in patients with kidney failure treated with hemodialysis:a randomized crossover study[J]. Am J Kidney Dis,2015,65(6):916-924.
[8] Ohno Y,Kitahara H,Fujii K,et al. High residual platelet reactivity after switching from clopidogrel to low-dose prasugrel in Japanese patients with end-stage renal disease on hemodialysis[J]. J Cardiol,2019,73(1):51-57.
[9] Deharo P,Pankert M,Quilici J,et al. Chronic kidney disease has a significant impact on platelet inhibition of new P2Y12 inhibitors[J]. Int J Cardiol,2015,184:428-430.
[10] 中华医学会心血管病学分会动脉粥样硬化与冠心病学组,中华医学会心血管病学分会介入心脏病学组,中国医师协会心血管内科医师分会血栓防治专业委员会,等. 冠心病双联抗血小板治疗中国专家共识[J]. 中华心血管病杂志,2021,49(5):432-454.
[11] Collet JP,Thiele H,Barbato E,et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation[J]. Eur Heart J,2021,42(14):1289-1367.
[12] Gragnano F,Heg D,Franzone A,et al. PRECISE-DAPT score for bleeding risk prediction in patients on dual or single antiplatelet regimens:insights from the GLOBAL LEADERS and GLASSY[J]. Eur Heart J Cardiovasc Pharmacother,2022,8(1):28-38.
[13] Faridi KF,Garratt KN,Kennedy KF,et al. Physician and hospital utilization of P2Y12 inhibitors in ST-segment-elevation myocardial infarction in the United States:a study from the National Cardiovascular Data Registry’s Research to Practice Initiative[J]. Circ Cardiovasc Qual Outcomes,2020,13(3):e006275.
[14] Peters RJ,Mehta SR,Fox KA,et al. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes:observations from the Clopidogrel in Unstable angina to prevent Recurrent Events(CURE) study[J]. Circulation,2003,108(14):1682-1687.
[15] Best PJ,Steinhubl SR,Berger PB,et al. The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease:results from the Clopidogrel for the Reduction of Events During Observation(CREDO) trial[J]. Am Heart J,2008,155(4):687-693.
[16] Chen YT,Chen HT,Hsu CY,et al. Dual antiplatelet therapy and clinical outcomes after coronary drug-eluting stent implantation in patients on hemodialysis[J]. Clin J Am Soc Nephrol,2017,12(2):262-271.
[17] Gimbel M,Qaderdan K,Willemsen L,et al. Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome(POPular AGE):the randomised,open-label,non-inferiority trial[J]. Lancet,2020,395(10233):1374-1381.
[18] Mavrakanas TA,Kamal O,Charytan DM. Prasugrel and ticagrelor in patients with drug-eluting stents and kidney failure[J]. Clin J Am Soc Nephrol,2021,16(5):757-764.
[19] Park S,Choi YJ,Kang JE,et al. P2Y12 antiplatelet choice for patients with chronic kidney disease and acute coronary syndrome:a systematic review and meta-analysis[J]. J Pers Med,2021,11(3):222.
[20] Laine M,Lemesle G,Burtey S,et al. TicagRelor Or Clopidogrel in severe or terminal chronic kidney patients Undergoing PERcutaneous coronary intervention for acute coronary syndrome:the TROUPER trial[J]. Am Heart J,2020,225:19-26.
[21] de Filippo O,D’ascenzo F,Raposeiras-Roubin S,et al. P2Y12 inhibitors in acute coronary syndrome patients with renal dysfunction:an analysis from the RENAMI and BleeMACS projects[J]. Eur Heart J Cardiovasc Pharmacother,2020,6(1):31-42.
[22] James S,Budaj A,Aylward P,et al. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function:results from the Platelet Inhibition and Patient Outcomes(PLATO) trial[J]. Circulation,2010,122(11):1056-1067.
[23] Baber U,Chandrasekhar J,Sartori S,et al. Associations between chronic kidney disease and outcomes with use of prasugrel versus clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention:a report from the PROMETHEUS study[J]. JACC Cardiovasc Interv,2017,10(20):2017-2025.
[24] W?hrle J,Seeger J,Lahu S,et al. Ticagrelor or prasugrel in patients with acute coronary syndrome in relation to estimatedglomerular filtration rate[J]. JACC Cardiovasc Interv,2021,14(17):1857-1866.
[25] Jain N,Phadnis MA,Hunt SL,et al. Comparative effectiveness and safety of oral P2Y12 inhibitors in patients on chronic dialysis[J]. Kidney Int Rep,2021,6(9):2381-2391.
[26] Charytan DM,Natwick T,Solid CA,et al. Comparative effectiveness of medical therapy,percutaneous revascularization,and surgical coronary revascularization in cardiovascular risk subgroups of patients with CKD:a retrospective cohort study of medicare beneficiaries[J]. Am J Kidney Dis,2019,74(4):463-473.
[27] Bangalore S,Maron DJ,O’brien SM,et al. Management of coronary disease in patients with advanced kidney disease[J]. N Engl J Med,2020,382(17):1608-1618.
[28] Fihn SD,Blankenship JC,Alexander KP,et al. 2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease[J]. Circulation,2014,130(19):1749-1767.
[29] Bonaca MP,Bhatt DL,Cohen M,et al. Long-term use of ticagrelor in patients with prior myocardial infarction[J]. N Engl J Med,2015,372(19):1791-1800.
[30] Mavrakanas TA,Chatzizisis YS,Gariani K,et al. Duration of dual antiplatelet therapy in patients with CKD and drug-eluting stents:a meta-analysis[J]. Clin J Am Soc Nephrol,2019,14(6):810-822.
[31] Park S,Kim Y,Jo HA,et al. Clinical outcomes of prolonged dual antiplatelet therapy after coronary drug-eluting stent implantation in dialysis patients[J]. Clin Kidney J,2020,13(5):803-812.
[32] Watanabe H,Domei T,Morimoto T,et al. Very short dual antiplatelet therapy after drug-eluting stent implantation in patients with high bleeding risk:insight from the STOPDAPT-2 trial[J]. Circulation,2019,140(23):1957-1959.
[33] Tomaniak M,Chichareon P,Klimczak-Tomaniak D,et al. Impact of renal function on clinical outcomes after PCI in ACS and stable CAD patients treated with ticagrelor:a prespecified analysis of the GLOBAL LEADERS randomized clinical trial[J]. Clin Res Cardiol,2020,109(7):930-943.
[34] Kim BK,Hong SJ,Cho YH, et al. Effect of ticagrelor monotherapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome:the TICO randomized clinical trial[J]. JAMA,2020,323(23):2407-2416.
相似文献/References:
[1]杜钧,佘强.冠心病抗炎治疗的临床研究进展[J].心血管病学进展,2016,(1):32.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.009]
DU Jun,SHE Qiang.Clinical Research Progress of Anti-inflammatory Therapy of Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2016,(7):32.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.009]
[2]努热曼古丽·阿布都克热木,马依彤.重度左心室收缩功能不全的冠心病患者血运重建治疗疗效及预后的评价[J].心血管病学进展,2016,(1):46.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.012]
NUREMANGULI·Abudukeremu,MA Yitong.Evaluation of Efficacy and Prognosis of Revascularization Therapy on Patients
with Coronary Heart Disease and Severe Left Ventricular Systolic Dysfunction[J].Advances in Cardiovascular Diseases,2016,(7):46.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.012]
[3]刘洋,综述,伍贵富,等.增强型体外反搏治疗冠心病的新机制[J].心血管病学进展,2016,(2):185.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.023]
LIU Yang,WU Guifu.New Mechanism of Enhanced External Counterpulsation for
Treatment of Coronary Artery Disease[J].Advances in Cardiovascular Diseases,2016,(7):185.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.023]
[4]杨洋,综述,沈比先,等.心脏核磁共振评估缺血性心脏病的应用价值[J].心血管病学进展,2016,(2):204.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.028]
YANG Yang,SHEN Bixian.Value of Cardiac Magnetic Resonance Assessment of Ischemic Heart Disease[J].Advances in Cardiovascular Diseases,2016,(7):204.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.028]
[5]史敬,综述,马依彤,等.n-3多不饱和脂肪酸对心血管疾病的临床应用[J].心血管病学进展,2016,(3):278.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.016]
SHI Jing,MA Yitong.Effects of n-3 Polyunsaturated Fatty Acids on Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2016,(7):278.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.016]
[6]高柳,袁晋青.重复支架置入术治疗药物洗脱支架再狭窄的研究进展[J].心血管病学进展,2015,(5):555.[doi:10.3969/j.issn.1004-3934.2015.05.008]
GAO Liu,YUAN Jingqing.Progress in Treatment for Drug-eluting Stent Restenosis by
Re-implementation of Stents[J].Advances in Cardiovascular Diseases,2015,(7):555.[doi:10.3969/j.issn.1004-3934.2015.05.008]
[7]邓文政,邓平.MG53蛋白的研究进展[J].心血管病学进展,2015,(5):626.[doi:10.3969/j.issn.1004-3934.2015.05.027]
DENG Wenzheng,DENG Ping.Research Progress of MG53[J].Advances in Cardiovascular Diseases,2015,(7):626.[doi:10.3969/j.issn.1004-3934.2015.05.027]
[8]陈静,李兴德.冠心病患者服药依从性的研究进展[J].心血管病学进展,2015,(6):728.[doi:10.3969/j.issn.1004-3934.2015.06.018]
CHEN Jing,LI Xingde.Advances in Medication Adherence of Patients with Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2015,(7):728.[doi:10.3969/j.issn.1004-3934.2015.06.018]
[9]姚雯,毛露,孙硕,等.心源性外泌体作为冠心病标志物和新靶点展望[J].心血管病学进展,2019,(6):844.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.002]
YAO Wen,MAO Lu,SUN Shuo,et al.Exogenous Exosome as A New Marker and Target of Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2019,(7):844.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.002]
[10]郭彩艳 靳春荣.腺苷药物在心血管疾病诊治中的应用进展[J].心血管病学进展,2019,(7):1011.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.012]
GUO CaiyanJIN Chunrong.Progress in the Application of Adenosine Drugs in the Diagnosis and Treatment of Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2019,(7):1011.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.012]